Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 3, 2013, Pages 403-410

  Roivainen, Anne ^a   Hautaniemi, Sannamari ^a   Möttönen, Timo ^a   Nuutila, Pirjo ^a   Oikonen, Vesa ^a   Parkkola, Riitta ^a   Pricop, Luminita ^b   Ress, Rudyard ^b   Seneca, Nicholas ^c   Seppänen, Marko ^a   Yli Kerttula, Timo ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b HOFFMANN LA ROCHE INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Antirheumatic therapy; Fluorodeoxyglucose; Positron emission tomography computed tomography; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DAS28; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; RHEUMATOID ARTHRITIS; SCREENING; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG COMBINATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SCINTISCANNING; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUG COMBINATIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TIME FACTORS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84874000776     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2282-x     Document Type: Article

References (23)

1. Polisson RP, Schoenberg OI, Fischman A, Rubin R, Simon LS, Rosenthal D, et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:819-25.
2. Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Möttönen T, et al. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum. 2003;48:3077-84.
3. Beckers C, Ribbens C, André B, Marcelis S, Kaye O, Mathy L, et al. Assessment of disease activity in rheumatoid arthritis with 18F-FDG PET. J Nucl Med. 2004;45:956-64.
4. Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med. 2006;31:386-90.
5. Elzinga EH, van der Laken CJ, Comans EF, Boellaard R, Hoekstra OS, Dijkmans BA, et al. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med. 2011;52:77-80.
6. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography imaging in non-malignant thoracic disorders. Semin Nucl Med. 2002;32:293-321.
7. Rennen HJ, Boerman OC, Oyen WJ, Corstens FH. Imaging infection/ inflammation in the new millennium. Eur J Nucl Med Mol Imaging. 2001;28:241-52.
8. Manthey N, Reinhard P, Moog F, Knesewitsch P, Hahn K, Tatsch K. The use of [18F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl Med Commun. 2002;23:645-53.
9. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-6.
10. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353:1568-73.
11. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
13. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.
14. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34-40.
15. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-45.
16. Teräs M, Tolvanen T, Johansson JJ, Williams JJ, Knuuti J. Performance of the new generation of whole-body PET/CT scanners: discovery STE and discovery VCT. Eur J Nucl Med Mol Imaging. 2007;34:1683-92.
17. Thie JA. Clarification of a fractional uptake concept. J Nucl Med. 1995;36:711-2.
18. Palmer WE, Rosenthal DI, Schoenberg OI, Fischman AJ, Simon LS, Rubin RH, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;196:647-55.
19. Beckers C, Jeukens X, Ribbens C, André B, Marcelis S, Leclercq P, et al. 18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging. 2006;33:275-80.
20. Valentin DJ. Radiation dose to patients from radiopharmaceuticals. Recalculated dose data for 19 frequently used radiopharmaceuticals from ICRP publication 53. Ann ICRP. 1998;28:47-83.
21. Overbeek F, Pauwels EK, Broerse JJ. Carcinogenic risk in diagnostic nuclear medicine: biological and epidemiological considerations. Eur J Nucl Med. 1994;21:997-1012.
22. Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS. How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging. 2006;33:S16-21.
23. Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW, Hoetjes NJ, et al. Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging. 2011;38:832-42.